Citigroup’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-41,200
| Closed | -$248K | – | 7949 |
|
|
2019
Q4 | $248K | Buy |
41,200
+4,900
| +13% | +$28.4K | ﹤0.01% | 5006 |
|
|
2019
Q3 | $131K | Buy |
36,300
+29,600
| +442% | +$114K | ﹤0.01% | 5483 |
|
|
2019
Q2 | $18K | Sell |
6,700
-13,200
| -66% | -$39K | ﹤0.01% | 7134 |
|
|
2019
Q1 | $59K | Sell |
19,900
-37,400
| -65% | -$91.9K | ﹤0.01% | 6203 |
|
|
2018
Q4 | $91K | Buy |
57,300
+26,100
| +84% | +$73.8K | ﹤0.01% | 5731 |
|
|
2018
Q3 | $115K | Buy |
31,200
+13,500
| +76% | +$40.2K | ﹤0.01% | 5767 |
|
|
2018
Q2 | $50K | Sell |
17,700
-16,900
| -49% | -$57.6K | ﹤0.01% | 6295 |
|
|
2018
Q1 | $128K | Sell |
34,600
-37,000
| -52% | -$121K | ﹤0.01% | 5391 |
|
|
2017
Q4 | $206K | Buy |
71,600
+6,900
| +11% | +$25.1K | ﹤0.01% | 5013 |
|
|
2017
Q3 | $291K | Buy |
64,700
+48,200
| +292% | +$214K | ﹤0.01% | 4648 |
|
|
2017
Q2 | $76K | Sell |
16,500
-12,200
| -43% | -$49K | ﹤0.01% | 5537 |
|
|
2017
Q1 | $121K | Sell |
28,700
-200
| -0.7% | -$830 | ﹤0.01% | 5069 |
|
|
2016
Q4 | $119K | Sell |
28,900
-12,000
| -29% | -$63.8K | ﹤0.01% | 5671 |
|
|
2016
Q3 | $331K | Sell |
40,900
-300
| -0.7% | -$2.55K | ﹤0.01% | 4267 |
|
|
2016
Q2 | $321K | Sell |
41,200
-17,300
| -30% | -$148K | ﹤0.01% | 4071 |
|
|
2016
Q1 | $452K | Sell |
58,500
-14,900
| -20% | -$109K | ﹤0.01% | 4236 |
|
|
2015
Q4 | $792K | Buy |
73,400
+35,700
| +95% | +$325K | ﹤0.01% | 3386 |
|
|
2015
Q3 | $261K | Sell |
37,700
-22,000
| -37% | -$179K | ﹤0.01% | 4296 |
|
|
2015
Q2 | $529K | Buy |
59,700
+1,800
| +3% | +$17K | ﹤0.01% | 3650 |
|
|
2015
Q1 | $571K | Buy |
57,900
+26,000
| +82% | +$325K | ﹤0.01% | 3614 |
|
|
2014
Q4 | $391K | Buy |
+31,900
| New | +$390K | ﹤0.01% | 4110 |
|
Citigroup's ACHN Position: Q1 2020 in Review
Citigroup sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 107,635 shares — an estimated $649K sold.
Citigroup first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $2.24M in Q4 2016. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citigroup reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 107,635 Achillion Pharmaceuticals shares in Q1 2020, an estimated $649K.
- Citigroup first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citigroup's Achillion Pharmaceuticals position peaked at $2.24M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.